Tumor Rebiopsy During Progression Under Immunotherapy for Patients With Lung Cancer

Not Applicable

Recruiting

• Conditions: Lung Cancer
• Interventions: Procedure: Rebiopsy

• Registration Number: NCT04300062
• Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Brief Summary

The objective of the study aims to collect tumor tissue at the moment of progression under Immune checkpoint inhibitors (ICI) in biological resources center in Ambroise Paré hospital, in order to insure later study on molecular mechanism involving the progression of NSCLC and SCLC under ICI.

The further analysis of research will be performed in the EA 4340 unity, Biomarkers and Clinical Trials in cancerology and onco-hematology, UVSQ, University of Paris-Saclay.

Detailed Description

The study will consist of creation a tumor tissue bank, all sampling will be stored in the biological resources center of Ambroise Paré hospital.

Study Timeline

• Study First Submitted: 2020-03-02
• Study First Submitted QC: 2020-03-06
• Study First Posted: 2020-03-09
• Study Start: 2020-08-18
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-17
• Last Update Posted: 2025-03-19
• Primary Completion: 2027-08
• Study Completion: 2027-08

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Diagnosed NSCLC or SCLC;
• Patient treated priorly by ICI and progressed under ICI;
• Have provided written informed consent for the study;
• Be >/= 18 years of age on day of signing informed consent.

Exclusion Criteria

• Patient under guardianship or curatorship;
• Unable to provide written informed consent for the study;
• Technical impossibility to carry out tissular rebiopsy under local anesthesia.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Rebiopsy	Rebiopsy	-

Primary Outcome Measures

Name	Time	Method
Incidence of specific histomolecular resistance	At the end of study, up to 2 years	Banking of tumor samples at progression with immune checkpoint inhibitor (ICI) in lung cancer, to evaluate the incidence of specific histomolecular resistance mechanisms to ICI by immunohistochemistry and molecular testing.

Trial Locations

Locations (1)

Service de Pneumologie et Oncologie thoracique, Hôpital Ambroise Paré, APHP; 🇫🇷 Boulogne-Billancourt, France